Dendritic cells, chemokine receptors and autoimmune inflammatory diseases.
Dendritic cells (DC) have been implicated in the induction of autoimmune diseases and have been identified in lesions associated with several autoimmune inflammatory diseases. Since DC are regarded as the professional antigen-presenting cell (APC) of the immune system and the only APC capable of activating naïve T cells, they are likely to play a significant role in breaking tolerance of self-reactive lymphocytes and in supporting autoimmune responses in these diseases. A number of studies have revealed that small molecular weight chemotactic proteins known as chemokines are present within the autoimmune lesions and may contribute to the recruitment not only of DC populations, but also of immune cells such as T cells, B cells, neutrophils and monocytes into the site, and to the formation of organized lymphoid tissue structures within the target organ. The focus of this review will be a discussion of the role of chemokines in the recruitment of DC in human autoimmune inflammatory disorders, specifically the trafficking of DC into the inflammatory sites and the subsequent migration of differentiated DC from the inflammatory sites into the draining lymph nodes. Once DC are properly positioned within the lymph nodes, circulating antigen specific naïve T cells can interact with DC and become activated, clonally expanded and stimulated to undergo differentiation into antigen-experienced memory T cells. Subsequent reactivation of memory T cells that enter the autoimmune lesions by DC present in the inflammatory lesion is thought to play a central role in tissue inflammation.
Cravens
Petra D
PD
Division of Infectious Diseases, University of Texas Southwestern Medical Center at Dallas, USA.
Lipsky
Peter E
PE
D000328:Adult; D017951:Antigen Presentation; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000473:pathology; D001327:Autoimmune Diseases / Q000276:immunology* / Q000473:pathology; D002465:Cell Movement; D002478:Cells, Cultured / Q000378:metabolism; D018925:Chemokines / Q000502:physiology; D002633:Chemotaxis; D003713:Dendritic Cells / Q000145:classification / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000473:pathology; D005786:Gene Expression Regulation / Q000187:drug effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006801:Humans; D007249:Inflammation; D015847:Interleukin-4 / Q000494:pharmacology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000473:pathology; D008213:Lymphocyte Activation; D018448:Models, Immunological; D009103:Multiple Sclerosis / Q000276:immunology / Q000473:pathology; D011565:Psoriasis / Q000276:immunology / Q000473:pathology; D019707:Receptors, Chemokine / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D012859:Sjogren's Syndrome / Q000276:immunology / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000276:immunology
D018925:Chemokines; D019707:Receptors, Chemokine; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor